Astralis Ltd. Selects Allen & Caron for Corporate Communications, Investor and Media Relations

Astralis Ltd. Selects Allen & Caron for Corporate Communications,
Investor and Media Relations 


FAIRFIELD, N.J., May 3  /PRNewswire-FirstCall/ -- Astralis Ltd.  (BULLETIN
BOARD: ASTR)  a biotechnology company engaged in the research and development
of novel treatments for immune system disorders and skin diseases, announced
that it has selected Irvine, CA-based Allen & Caron Inc as its corporate
communications, investor relations and media relations agency.

Astralis currently has one product in clinical development, Psoraxine(R), now
in Phase II clinical trials, for the treatment of psoriasis.  A proprietary
protein extract, Psoraxine represents an innovative approach to the treatment
of the disease, as it appears to act through a mechanism of immuno-stimulation,
as opposed to the immuno-suppression techniques used by some existing biologic
therapies.  The Company also has pre-clinical focus in other areas including
eczema, seborrheic dermatitis, psoriatic arthritis, rheumatoid arthritis and
leishmaniasis.

Astralis CEO Mike Ajnsztajn commented, "We have arrived at the place in our
strategic plan that calls for increased communication with professional
investment audiences, both in the US and abroad, and we have selected Allen &
Caron due to their experience and ability in assisting companies wishing to
position themselves properly within the investment community.  We believe that
Allen & Caron should be able to help us with the dissemination of our corporate
information to the Street, as well as to industry and financial media."

Allen & Caron Chairman and CEO, Joe Allen, said, "Astralis's proprietary
technology platform, and resulting therapy, Psoraxine, position the Company in
front of some very large potential market opportunities.  According to the
National Psoriasis Foundation, psoriasis affects more than 4.5 million people
in the US alone.  We believe that Astralis presents an interesting and
compelling story to Wall Street and we look forward to working with them to
broaden their audience, by increasing overall awareness among US institutional
investors and the international media."

About Allen & Caron Inc

Allen & Caron is a full service corporate, investor and marketing
communications agency serving the needs of public companies.  The Allen & Caron
international client base includes emerging growth companies in a range of
industry segments.  The firm maintains offices in Irvine, CA, New York City and
London.  For more information, please visit http://www.allencaron.com/.

About Astralis Ltd.

Fairfield, NJ-based Astralis is a development-stage biotechnology company
engaged in the research and development of novel treatments for immune system
disorders and skin diseases.  The Company's current activities focus on the
development of a product candidate named Psoraxine(R) -- now in Phase II
clinical trials -- for the treatment of psoriasis.  Psoraxine is a proprietary
protein extract with a mechanism of action that is believed to be based on
immuno-stimulation.  Astralis is also engaged in research on the possible
development of the technology underling Psoraxine for the treatment of other
indications, such as eczema, seborrheic dermatitis, psoriatic arthritis,
rheumatoid arthritis and leishmaniasis.

In January 2004, Astralis received its first patent from the United States
Patent Office.  For more information, please visit http://www.astralisltd.com/.

This press release may contain "forward-looking statements", as defined by the
Private Securities Litigation Reform Act of 1995, regarding Astralis Ltd.,
including with respect to the objectives, intentions, and expectations relating
to clinical studies.  Clinical results may differ materially from those
described in the press release as a result of a number of factors. There can be
no assurance that Psoraxine(R) will be successfully developed or manufactured,
or that final results of human clinical trials will result in the regulatory
approvals required to market products, or that final regulatory approval will
be received in a timely manner, if at all, or that patient and physician
acceptance of this product will be achieved.  Other factors that could cause
actual results to differ materially from anticipated results include, but are
not limited to, those risks and uncertainties detailed in the Company's annual
report on Form 10-KSB and other reports filed from time to time with the
Securities and Exchange Commission.  Astralis Ltd. undertakes no obligation to
revise or update any forward-looking statement herein to reflect events or
circumstances after the date of this release.

For further information, please contact: Investors, Jay F. McKeage, , or Media,
Brian Kennedy, , both of Allen & Caron Inc, [phone], for Astralis Ltd.;
or Mike Ajnsztajn, Chief Executive Officer, or Gina Tedesco, Chief Financial
Officer, both of Astralis Ltd., [phone], . 

DATASOURCE: Allen & Caron Inc



CONTACT:  investors, Jay F. McKeage, , or media, Brian

Kennedy, , both of Allen & Caron Inc, [phone], for

Astralis Ltd.; or Mike Ajnsztajn, Chief Executive Officer, or Gina Tedesco,

Chief Financial Officer, both of Astralis Ltd., [phone],





Web site:  http://www.astralisltd.com/ 

Web site:  http://www.allencaron.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/133897.html 

Copyright